• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Yield10 Bioscience Announces Adjournment of Special Meeting of Stockholders to Solicit Sufficient Votes in Favor of the Key Proposals

    11/8/24 11:20:00 AM ET
    $YTEN
    Get the next $YTEN alert in real time by email

    Special Meeting Adjourned to Thursday, November 21, 2024

    WOBURN, MA / ACCESSWIRE / November 8, 2024 / Yield10 Bioscience, Inc. (OTCQB:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that its Special Meeting of Stockholders (the "Special Meeting"), scheduled to be held at 11:00 a.m., Eastern Time, on November 8, 2024, was convened and adjourned, without any business being conducted, due to lack of sufficient votes in favor of the key proposals related to the Asset Sale to Nuseed and the Dissolution proposal.

    To pass the proposals, more than 50% of the shares of common stock outstanding and entitled to vote as of the close of business on October 3, 2024 (the record date for the Special Meeting) must be voted in favor of the key Proposals 1 and 2. Due to the lack of sufficient votes in favor of the proposals as of November 8, 2024, the Special Meeting of Stockholders was adjourned to 11:00 a.m., Eastern Time, on Thursday, November 21, 2024, to allow additional time for Yield10's stockholders to vote on the proposals set forth in Yield10's definitive proxy statement filed with the Securities and Exchange Commission (the "SEC") on October 16, 2024.

    The board of directors and management of Yield10 request stockholders as of the record date to please vote their proxies as soon as possible. During the current adjournment, Yield10 will continue to solicit votes from its stockholders with respect to the proposals set forth in Yield10's proxy statement. Only stockholders of record as of the record date, October 3, 2024, are entitled to and are being requested to vote. Proxies previously submitted in respect of the Special Meeting will be voted at the adjourned Special Meeting unless properly revoked, and stockholders who have previously submitted a proxy or otherwise voted need not take any action.

    Oliver Peoples, Ph.D. President and Chief Executive Officer of Yield10 commented, "We are very grateful to our stockholders who have voted their proxies over the past three weeks. We continue to strongly encourage all Yield10 stockholders eligible to vote to review the proxy materials and participate in voting, as the proposed asset sale to Nuseed is the only avenue under which stockholders would potentially receive a payment for their shares."

    For stockholders having any questions or requiring further assistance in voting shares, please contact Yield10's proxy solicitation agent Alliance Advisors toll-free at 855-643-7305. Yield10 encourages all stockholders of record who have not yet voted, to do so by November 20, 2024 at 11:59 p.m., Eastern time.

    If the number of additional shares of common stock voted at the adjourned Special Meeting is not sufficient to reach a favorable vote on the Asset Sale to Nuseed and the Dissolution Proposal, Yield10 may determine to adjourn the Special Meeting again, which would require Yield10 to incur additional costs.

    Important Information

    This material may be deemed to be solicitation material in respect of the Special Meeting to be reconvened and held on November 14, 2024. In connection with the Special Meeting, Yield10 filed with the SEC a definitive proxy statement on October 16, 2024. BEFORE MAKING ANY VOTING DECISIONS, STOCKHOLDERS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE SPECIAL MEETING. A notice of the Special Meeting, a proxy card, and the definitive proxy statement were mailed to stockholders who are entitled to vote at the Special Meeting. No changes have been made to the proposals to be voted on by stockholders at the Special Meeting. Yield10's proxy statement and any other materials filed by Yield10 with the SEC can be obtained free of charge at Yield10's website SEC Filings | Yield10 Bioscience, Inc.or the SEC's website at www.sec.gov.

    About Yield10 Bioscience

    Yield10 Bioscience, Inc. ("Yield10" or the "Company") is an agricultural bioscience company that is leveraging advanced genetics to develop the oilseed Camelina sativa ("Camelina") as a platform crop for large-scale production of sustainable seed products. These seed products include feedstock oils for renewable diesel and sustainable aviation biofuels and omega-3 (EPA and DHA+EPA) oils for pharmaceutical, nutraceutical and aquafeed applications. Yield10 is headquartered in Woburn, MA. For more information about the company, please visit www.yield10bio.com

    (YTEN-G)

    Safe Harbor for Forward-Looking Statements

    This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this releasedo not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical, including, without limitation, statements related to the adjourned Special Meeting and Yield10's ability to solicit sufficient votes in favor of the proposals contemplated at such meeting, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, but not limited to, the Company's ability to secure adequate funding in the near term to continue operations, as to which no assurance can be given, as well as the risks and uncertainties detailed in Yield10 Bioscience's filings with the SEC. Yield10 assumes no obligation to update any forward-looking information contained in this press release or with respect to the matters described herein.

    Contacts:

    Yield10 Bioscience
    LynneH. Brum, (617) 682-4693 ,[email protected]

    SOURCE: Yield10 Bioscience, Inc.



    View the original press release on accesswire.com

    Get the next $YTEN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $YTEN

    DatePrice TargetRatingAnalyst
    2/8/2024Buy → Hold
    Lake Street
    3/10/2022$18.00 → $9.00Buy
    Maxim Group
    More analyst ratings

    $YTEN
    Leadership Updates

    Live Leadership Updates

    See more
    • Yield10 Bioscience Appoints Willie Loh, Ph.D., Former Cargill Executive, to the Board of Directors

      WOBURN, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that Willie Loh, Ph.D., was named to the Company's Board of Directors effective October 4, 2022. Dr. Loh previously served as a Special Commercial and Technical Advisor to the Company. Dr. Loh was formerly Vice President, Market Development of Cargill Inc.'s Global Edible Oils Solutions group in North America. Cargill is a global food and agriculture company. "We are delighted that Willie is expanding his role with Yield10 by serving on our Board of Directors," said Oliver Peoples, Ph.D., Chief Executive Officer of Yield1

      10/5/22 8:30:20 AM ET
      $YTEN

    $YTEN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Yield10 Bioscience Announces Adjournment of Special Meeting of Stockholders to Solicit Sufficient Votes in Favor of the Key Proposals

      Special Meeting Adjourned to Thursday, November 21, 2024 WOBURN, MA / ACCESSWIRE / November 8, 2024 / Yield10 Bioscience, Inc. (OTCQB:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that its Special Meeting of Stockholders (the "Special Meeting"), scheduled to be held at 11:00 a.m., Eastern Time, on November 8, 2024, was convened and adjourned, without any business being conducted, due to lack of sufficient votes in favor of the key proposals related to the Asset Sale to Nuseed and the Dissolution proposal.To pass the proposals, more than 50% of the shares of common stock outstanding and entitled to vote as of the close of business on October 3, 2024

      11/8/24 11:20:00 AM ET
      $YTEN
    • Yield10 Bioscience Announces Second Quarter 2024 Financial Results

      WOBURN, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today reported financial results for the second quarter ended June 30, 2024. "We continue to work closely with the Nufarm team to finalize the asset purchase agreement announced in July," said Oliver Peoples, Ph.D., President and Chief Executive Officer of Yield10. "We believe that the transition of our Omega-3 Camelina program to Nufarm is in the best interest of our shareholders, business partners, and employees. Receipt of the initial $3 million payment and progress toward earning an additional $2 million milestone payment is enabling

      8/14/24 4:37:26 PM ET
      $YTEN
    • Yield10 Bioscience Grants Nufarm a Commercial License to Omega-3 Assets for Producing Oil in Camelina, and Yield10 and Nufarm sign a Memorandum of Understanding for Sale of Assets

      WEST SACRAMENTO, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (OTC:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that the Company has signed a Memorandum of Understanding ("MOU") and License Agreement with Nuseed Nutritional US Inc. (the seed technologies platform of Nufarm Limited (ASX:NUF)), granting Nufarm a commercial license to certain Omega-3 intellectual property assets, materials and know-how for producing oil in Camelina. Nufarm and Yield10 have additionally agreed to immediately negotiate exclusively with each other for the sale of Yield10's remaining assets to Nufarm. The asset sale will require an affirmative vote

      7/17/24 6:45:00 PM ET
      $YTEN

    $YTEN
    SEC Filings

    See more
    • Yield10 Bioscience Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Costs Associated with Exit or Disposal Activities, Leadership Update, Financial Statements and Exhibits

      8-K - YIELD10 BIOSCIENCE, INC. (0001121702) (Filer)

      12/6/24 4:57:07 PM ET
      $YTEN
    • Yield10 Bioscience Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - YIELD10 BIOSCIENCE, INC. (0001121702) (Filer)

      11/22/24 10:39:21 AM ET
      $YTEN
    • Yield10 Bioscience Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

      8-K - YIELD10 BIOSCIENCE, INC. (0001121702) (Filer)

      11/12/24 11:49:02 AM ET
      $YTEN

    $YTEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • VP Research and CSO Snell Kristi covered exercise/tax liability with 877 shares, decreasing direct ownership by 11% to 6,999 units (SEC Form 4)

      4 - YIELD10 BIOSCIENCE, INC. (0001121702) (Issuer)

      8/20/24 3:15:23 PM ET
      $YTEN
    • VP Planning and Communications Brum Lynne H covered exercise/tax liability with 731 shares, decreasing direct ownership by 11% to 5,867 units (SEC Form 4)

      4 - YIELD10 BIOSCIENCE, INC. (0001121702) (Issuer)

      8/19/24 8:11:23 PM ET
      $YTEN
    • VP Finance and CAO Haaser Charles B covered exercise/tax liability with 731 shares, decreasing direct ownership by 11% to 5,949 units (SEC Form 4)

      4 - YIELD10 BIOSCIENCE, INC. (0001121702) (Issuer)

      8/19/24 8:10:36 PM ET
      $YTEN

    $YTEN
    Financials

    Live finance-specific insights

    See more

    $YTEN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $YTEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $YTEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Yield10 Bioscience Announces Fourth Quarter and Full Year 2023 Financial Results

      -Granted global commercial license to Vision Bioenergy for Camelina addressing the biofuel market-Advanced regulatory and seed scale-up program for omega-3 Camelina-E3902 oil trait in Camelina cleared by regulatory authority for planting in Canada-Management will host a conference call today at 4:30 p.m. (ET) to review financial results and provide a corporate update WOBURN, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today reported financial results for the fourth quarter and full year ended December 31, 2023. "In 2023 we successfully executed our plan and achieved several

      4/1/24 4:01:07 PM ET
      $YTEN
    • Yield10 Bioscience to Announce Fourth Quarter and Full Year 2023 Financial Results and Host a Conference Call on Monday, April 1, 2024

      WOBURN, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that the Company will report its fourth quarter and full year 2023 financial results and provide a corporate update on Monday, April 1, 2024. Management will host a conference call on Monday, April 1, 2024.at 4:30 p.m. ET to review financial results, share corporate highlights, and provide an overall business update. Following management's formal remarks, there will be a question and answer session. Interested parties within the U.S. should call 1-877-709-8150 or +1-201-689-8354 (international) to listen to the call. Th

      3/28/24 4:01:20 PM ET
      $YTEN
    • Yield10 Bioscience to Announce Third Quarter 2023 Financial Results and Host a Conference Call on Tuesday, November 14, 2023

      WOBURN, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today announced that the Company will report its third quarter 2023 financial results and provide a corporate update on Tuesday, November 14, 2023. Management will host a conference call on Tuesday, November 14, 2023 at 4:30 p.m. ET to review financial results, share corporate highlights, and provide an overall business update. Following management's formal remarks, there will be a question and answer session. Interested parties within the U.S. should call 1-800-715-9871 or +1-646-307-1963 (international) to listen to the call. The Conf

      11/8/23 8:31:35 AM ET
      $YTEN
    • Schuler Jack W bought $497,250 worth of shares (765,000 units at $0.65) (SEC Form 4)

      4 - YIELD10 BIOSCIENCE, INC. (0001121702) (Issuer)

      10/10/23 4:41:49 PM ET
      $YTEN
    • SEC Form SC 13D/A filed by Yield10 Bioscience Inc. (Amendment)

      SC 13D/A - YIELD10 BIOSCIENCE, INC. (0001121702) (Subject)

      5/23/24 5:51:39 PM ET
      $YTEN
    • SEC Form SC 13D filed by Yield10 Bioscience Inc.

      SC 13D - YIELD10 BIOSCIENCE, INC. (0001121702) (Subject)

      10/11/23 4:05:24 PM ET
      $YTEN
    • SEC Form SC 13D/A filed by Yield10 Bioscience Inc. (Amendment)

      SC 13D/A - YIELD10 BIOSCIENCE, INC. (0001121702) (Subject)

      5/26/23 1:14:08 PM ET
      $YTEN
    • Yield10 Bioscience downgraded by Lake Street

      Lake Street downgraded Yield10 Bioscience from Buy to Hold

      2/8/24 7:25:58 AM ET
      $YTEN
    • Maxim Group reiterated coverage on Yield10 Bioscience with a new price target

      Maxim Group reiterated coverage of Yield10 Bioscience with a rating of Buy and set a new price target of $9.00 from $18.00 previously

      3/10/22 9:38:04 AM ET
      $YTEN
    • Maxim Group reiterated coverage on Yield10 Bioscience with a new price target

      Maxim Group reiterated coverage of Yield10 Bioscience with a rating of Buy and set a new price target of $24.00 from $12.00 previously

      2/9/21 4:14:42 PM ET
      $YTEN